Jay Hagan is the founder of Regulus Therapeutics. Regulus Therapeutics has raised $1.7B in total funding. Latest round: IPO. Backed by Novartis AG.
Jay Hagan is associated with Regulus Therapeutics, a publicly-traded biotech firm based in San Diego. The company, founded nearly two decades ago, focuses on developing treatments targeting microRNAs and has a kidney-disease treatment called farabursen. Regulus Therapeutics was recently acquired by Novartis AG in a deal valued at up to $1.7 billion, with potential for an additional $900 million contingent on regulatory approval for farabursen.
Full founder directory · Investor directory · Company funding database · Fundraising library